Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice

Anticancer Drugs. 1991 Dec;2(6):549-53. doi: 10.1097/00001813-199112000-00005.

Abstract

The anti-cancer drug aclarubicin (2.0 mg/kg body weight) was injected into the left popliteal lymph node (the primary draining node of the foot-pad region) or into the tail vein, 8 days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells/mouse in the left hind paw foot-pad of mouse (donor). During this time, metastases were established in the lower para-aortic nodes (the secondary draining nodes of this region). On day 10, the lower para-aortic nodes taken from each donor were transferred intraperitoneally to a normal mouse (recipient). From the recipients' survival time, the viable P388 leukemia cell number in the para-aortic nodes per donor mouse was estimated with a calibration line. The recipients' survival curve in the intralymphatic chemotherapy group was statistically significantly better than that in the intravenous chemotherapy group.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aclarubicin / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Calibration
  • Disease Models, Animal
  • Female
  • Injections, Intralymphatic
  • Leukemia P388 / drug therapy*
  • Leukemia P388 / pathology
  • Lymphatic Metastasis / pathology*
  • Mice
  • Mice, Inbred Strains
  • Neoplasm Transplantation
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents
  • Aclarubicin